Swissmedic has approved Novartis’ Coartem Baby as the first malaria medicine for newborns and young infants, the company announced on Tuesday. The treatment was developed in collaboration with the Medicines for Malaria Venture (MMV). Novartis plans to distribute the treatment on a not-for-profit basis to areas where malaria is endemic. This includes the eight African… The post Swissmedic approves first malaria treatment for infants appeared first on Drug Discovery and Development.
